HIGHLIGHTS
- who: Ab and colleagues from the (UNIVERSITY) have published the research: Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20 + cancers with multiple mechanisms of action, in the Journal: (JOURNAL)
- what: The authors present that GB261, a novel CD20/CD3 BsAb designed from Rituximab, retains Fc effector function that only targets B cells and gains T_cell engager function with reduced CRS.
SUMMARY
In recent years, exciting technologies and platforms have been developed for the intricate design and production of anticancer immune reagents such as antibodies and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.